Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Hepatocellular × budigalimab × Clear all

Phase

Phase 1 4 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 7 lenvatinib 5 apatinib 5 Oxaliplatin 5 Fluorouracil 5 sintilimab 4 Leucovorin 4 Folfox protocol 4 Bevacizumab 4 camrelizumab 3 atezolizumab 3 Capecitabine 3 tremelimumab 2 durvalumab 2 Radiosurgery 2 Nivolumab 2 Neoadjuvant Therapy 2 Hepatectomy 2 Gemcitabine 2 Ethiodized Oil 2 Drug Therapy 2 pirarubicin 1 liposomal doxorubicin 1 lanreotide 1 halofantrine 1 donafenib 1 coenzyme Q10 1 budigalimab 1 Vitamin B 6 1 Tyrosine Kinase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06109272 2025-08-15

LIVIGNO-2

AbbVie

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡